Corbus Pharma Reports Director/Officer Changes & Shareholder Votes
Ticker: CRBP · Form: 8-K · Filed: May 20, 2024 · CIK: 1595097
Sentiment: neutral
Topics: leadership-change, governance, shareholder-vote
Related Tickers: CRBP
TL;DR
Corbus Pharma's leadership team is changing, and they're holding a shareholder vote.
AI Summary
Corbus Pharmaceuticals Holdings, Inc. filed an 8-K on May 20, 2024, reporting events as of May 16, 2024. The filing indicates changes related to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. It also covers the submission of matters to a vote of security holders and includes financial statements and exhibits.
Why It Matters
This filing signals potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational decisions.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with shareholder votes, can indicate internal shifts or strategic realignments that may carry inherent business risks.
Key Players & Entities
- Corbus Pharmaceuticals Holdings, Inc. (company) — Registrant
- May 16, 2024 (date) — Earliest event reported
- May 20, 2024 (date) — Date of report
FAQ
What specific changes occurred regarding directors or officers?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers, along with details on compensatory arrangements.
What matters were submitted to security holders for a vote?
The filing confirms the submission of matters to a vote of security holders.
What is the primary business of Corbus Pharmaceuticals Holdings, Inc.?
Corbus Pharmaceuticals Holdings, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
When is Corbus Pharmaceuticals Holdings, Inc.'s fiscal year end?
The company's fiscal year ends on December 31.
What is the Commission File Number for Corbus Pharmaceuticals Holdings, Inc.?
The Commission File Number is 001-37348.
Filing Stats: 1,520 words · 6 min read · ~5 pages · Grade level 12.1 · Accepted 2024-05-20 16:30:12
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CRBP The Nasdaq Capital M
Filing Documents
- crbp-20240516.htm (8-K) — 94KB
- crbp-ex10_1.htm (EX-10.1) — 204KB
- crbp-ex10_2.htm (EX-10.2) — 62KB
- crbp-ex10_3.htm (EX-10.3) — 61KB
- crbp-ex10_4.htm (EX-10.4) — 69KB
- crbp-ex10_5.htm (EX-10.5) — 67KB
- 0000950170-24-062436.txt ( ) — 743KB
- crbp-20240516.xsd (EX-101.SCH) — 24KB
- crbp-20240516_htm.xml (XML) — 5KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On May 16, 2024, the Company held its Annual Meeting. The matters voted on at the Annual Meeting were: (1) the election of directors, (2) the approval of the 2024 Plan, (3) the ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024 and (4) the approval, on an advisory basis, of the executive compensation of the Company's named executive officers. The final voting results were as follows: 1. The election of each of Yuval Cohen, Alan Holmer, Avery W. Catlin, Rachelle Jacques, John Jenkins, Peter Salzmann, Anne Altmeyer and Yong Ben as directors to hold office for a term of one year, until his or her successor is duly elected and qualified or he or she is otherwise unable to complete his or her term. The votes were cast for this matter as follows: Nominees Votes For Votes Withheld Broker Non-Votes Yuval Cohen 6,629,030 19,144 1,962,726 Alan Holmer 6,629,266 18,908 1,962,726 Avery W. Catlin 6,192,121 456,053 1,962,726 Rachelle Jacques 6,229,111 419,063 1,962,726 John Jenkins 6,192,908 455,266 1,962,726 Peter Salzmann 6,628,553 19,621 1,962,726 Anne Altmeyer 6,191,380 456,794 1,962,726 Yong Ben 6,629,521 18,653 1,962,726 2. The proposal to approve the 2024 Plan was approved based on the following votes: Votes For Votes Against Abstentions Broker Non-Votes 3,961,184 2,681,336 5,654 1,962,726 3. The proposal to ratify the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024 was approved based upon the following votes: Votes For Votes Against Abstentions 8,388,012 161,212 61,676 4. The votes were cast as follows with respect to the proposal to vote, on an advisory basis, on the compensation of th
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. 10.1 Corbus Pharmaceuticals Holdings, Inc. 2024 Equity Compensation Plan. 10.2 Form of Incentive Stock Option Grant Agreement. 10.3 Form of Non-Statutory Stock Option Grant Agreement. 10.4 Form of Restricted Stock Award Agreement. 10.5 Form of Restricted Stock Unit Award Agreement. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Corbus Pharmaceuticals Holdings, Inc. Dated: May 20, 2024 By: /s/ Yuval Cohen Name: Title: Yuval Cohen Chief Executive Officer